AbstractA novel cancer vaccine consisting of fixed autologous cancer tissue‐fragments, microparticles encapsulating cytokines, and an adjuvant was developed. In a Phase I/IIa clinical trial, vaccination to patients after resection of hepatocellular carcinoma induced significantly longer time before the first recurrence than that in historical control patients operated in the same department (P<0.05). This formulation will be promising against recurrence of many types of human cancers.
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً